Science
One of the most studied probiotics in the world
BioGaia’s probiotic products with L. reuteri are among the most scientifically well-documented probiotics in the world with regard to both efficacy and safety.
BioGaia’s different strains of L. reuteri have been studied in more than 290 clinical trials involving over 25,000 people of all ages (Dec 2025).
Studies have been performed on the following:
- Infantile colic and digestive health in children
- Immune modulation and infection protection
- Respiratory infections
- Antibiotic-associated side effects, such as diarrhea
- Adjunctive treatment of Helicobacter pylori infection
- Acute diarrhea
- Oral health, such as gingivitis and periodontitis
- Irritable bowel syndrome (IBS)
- Osteopenia
- Autism spectrum condition
- Urinary tract infections
61
studies in 7,873 subjects
Infants 0-12 months
31
studies in 4,290 subjects
Toddlers 13-36 months
47
studies in 4,657 subjects
Children 3-18 years
156
studies in 8,185 subjects
Adults >18 years
Research on bacteria
In the past decade, research on bacteria and their significance to our health has increased. At BioGaia, we have been researching Limosilactobacillus reuteri (formerly Lactobacillus reuteri) for more than 35 years. During the years, we built a unique research network of specialists at research institutes worldwide. Together we have learned and gained knowledge about several L. reuteri bacteria strains for various conditions.
BioGaia Science News Brief
Stay informed on the latest research within the probiotic field!
Subscribe to receive quarterly updates on our latest research developments, clinical studies, etc.